In April 2017, the FDA approved the first-ever drug treatment for the rare and aggressive skin cancer Merkel cell carcinoma (MCC). The immunotherapy drug avelumab (Bavencio, EMD Serono/Pfizer) was approved based on the results of a multicenter, open-label, phase 2 trial as well as data from a real-world retrospective analysis of patients with metastatic MCC treated with chemotherapy.